复方参芪丸对肺癌患者化放疗中减毒增效的临床研究

Clinical Study on Effect of Composite Shenqi Pill in Toxicity Reducing and Efficacy Enhancing on Chemo-and Radio-therapy in Patients with Lung Cancer

目的 :研究复方参芪丸对肺癌患者在化放疗过程中的减毒增效作用。方法 :6 0例肺癌患者随机分为两组。治疗组 (30例 )化疗或放疗与复方参芪丸同时应用 ,对照组 (30例 )化疗或放疗与一般生血药同时应用 ,两组均完成 2个疗程的化疗或三分之二疗程的放疗 ,并进行治疗前后细胞免疫功能与白细胞数测定。结果 :T细胞亚群CD3、CD4 、CD8和CD4 /CD8比值、淋巴细胞转化率、白细胞计数变化治疗组化放疗前后比较差异无显著性 (P >0 0 5 )。对照组放化疗前后比较差异有显著性 (P <0 0 1)。结论 :复方参芪丸在肺癌化放疗过程中具有保护骨髓 ,改善生活质量 ,提高机体免疫功能 。

Objective: To study the effect of composite Shenqi Pill (CSQP) in toxicity reducing and efficacy enhancing on chemo and radio therapy in patients with lung cancer. Methods: Sixty patients with lung cancer were randomly divided into two groups. In their therapeutic period of chemotherapy and/or radiotherapy, the 30 patients in the treated group were given CSQP and the 30 patients in the control group were given conventional hematogenic agents simultaneously. Over two courses of chemotherapy and/or 2/3 courses of radiotherapy were completed in all the patients. The peripheral blood levels of cellular immune function and white blood cell (WBC) count were examined before and after treatment. Results: The changes in T lymphocyte subsets CD 3, CD 4, CD 8 and CD 4/CD 8 ratio, lymphocyte transformation and WBC count in the treated group were unchanged after treatment, as compared with those before treatment, the difference was insignificant (P>0 05), but in the control group, the difference was significant (P<0 01). Conclusion: CSQP could protect the bone marrow, raise the immune function and improve the patients′ quality of life during the course of chemotherapy and radiotherapy, which displays the effects of toxicity reducing and efficacy enhancing in patients with lung cancer.